{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"24.7","value":"0"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"28.7","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Overall response rate is defined as the percentage of participants achieving a CR, mCR, or PR, per IWG criteria, where CR=Bone marrow: \\<=5% myeloblasts with normal maturation of all cell lines; PR=Bone marrow blasts decreased by \\>=50% over pre-treatment but still \\>5%; mCR= Bone marrow: ≤ 5% myeloblasts and decrease by \\>=50% over pre-treatment. Percentage values are rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG000","title":"Part 1: GSK3326595 400 mg"},{"description":"Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG001","title":"Part 1: GSK3326595 300 mg"}],"paramType":"NUMBER","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 30.8 months","title":"Part 1: Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}